Predicting Exposure after Oral Inhalation of the Selective Glucocorticoid Receptor Modulator, AZD5423, Based on Dose, Deposition Pattern, and Mechanistic Modeling of Pulmonary Disposition

Journal of Aerosol Medicine and Pulmonary Drug Delivery

Volumn 30, Issue 2, 2017, Pages 108-117

  Bäckman, Per ^a   Tehler, Ulrika ^a   Olsson, Bo ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

anatomical mouth Throat model; AZD5423; deposition pattern; dissolution; inhalation; mechanistic modeling; pharmacokinetics; selective glucocorticoid receptor modulator; simulation

Indexed keywords

ANTIASTHMATIC AGENT; AZD 5423; HORMONE RECEPTOR AFFECTING AGENT; UNCLASSIFIED DRUG; 2,2,2-TRIFLUORO-N-(1-((1-(4-FLUOROPHENYL)-1H-INDAZOL-5-YL)OXY)-1-(3-METHOXYPHENYL)-2-PROPANYL)ACETAMIDE; ACETAMIDE DERIVATIVE; GLUCOCORTICOID RECEPTOR; INDAZOLE DERIVATIVE;

ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHMA; CLINICAL ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISPOSITION; DRUG EXPOSURE; DRUG FORMULATION; DRUG SOLUBILITY; DRY POWDER INHALER; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MUCOCILIARY CLEARANCE; NEBULIZER; PARTICLE SIZE; PREDICTION; RESPIRATORY SYSTEM; SIMULATION; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUNTEER; ADOLESCENT; BIOAVAILABILITY; BIOLOGICAL MODEL; CHEMISTRY; COMPARATIVE STUDY; CROSSOVER PROCEDURE; DRUG EFFECTS; DRUG RELEASE; INHALATIONAL DRUG ADMINISTRATION; LUNG; METABOLISM; RANDOMIZED CONTROLLED TRIAL; SOLUBILITY; TISSUE DISTRIBUTION;

ACETAMIDES; ADMINISTRATION, INHALATION; ADOLESCENT; ANTI-ASTHMATIC AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG LIBERATION; HUMANS; INDAZOLES; LUNG; MALE; MODELS, BIOLOGICAL; MUCOCILIARY CLEARANCE; NEBULIZERS AND VAPORIZERS; PARTICLE SIZE; RECEPTORS, GLUCOCORTICOID; SOLUBILITY; TISSUE DISTRIBUTION;

EID: 85017156483     PISSN: 19412711     EISSN: 19412703     Source Type: Journal    
DOI: 10.1089/jamp.2016.1306     Document Type: Article

References (28)

1. Brutsche MH, Brutsche IC, Munavvar M, Langley SJ, Masterson CM, Daley-Yates PT, Brown R, Custovic A, and Woodcock A: Comparison of pharmacokinetics and systemic effects of inhaled fluticasone propionate in patients with asthma and healthy volunteers: A randomized crossover study. Lancet. 2000;356:556-561.
2. Harrison TW, and Tattersfield AE: Plasma concentrations of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects. Thorax. 2003;58:258-260.
3. Daley-Yates P, Mehta R, Chan R, Despa S, and Louey M: Pharmacokinetics and pharmacodynamics of fluticasone propionate and salmeterol delivered as a combination dry powder from a capsule-based inhaler and a multidose inhaler in asthma and COPD patients. J Aerosol Med Pulm Drug Deliv. 2013;26:1-11.
4. Olsson B, Borgström L, Lundbäck H, and Svensson M: Validation of a general in vitro approach for prediction of total lung deposition in healthy adults for pharmaceutical inhalation products. J Aerosol Med Pulm Drug Deliv. 2013;23:355-369.
5. Olsson B, and Bäckman P: Mouth-Throat models for realistic in vitro testing: A proposal for debate. In: RN Dalby, PR Byron, J Peart, J Suman, SJ Farr, and P Young, (eds). Proceedings of Respiratory Drug Delivery 2014. Volume 1. DHI Publishing, LLC, River Grove, IL; pp. 287-294, 2014.
6. Forbes B, Bäckman P, Christopher D, Dolovich M, Bing VL, and Morgan B: In vitro testing for orally inhaled products: Developments in science based regulatory approaches. AAPS J. 2015;17:837-852.
7. Wang YB, Watts AB, Peters JI, and Williams RO: The impact of pulmonary diseases on the fate of inhaled medicines-A review. Int J Pharmaceut. 2014;461:112-128.
8. US Food and Drug Administration: Draft Guidance on Fluticasone Propionate; Salmeterol Xinafoate. Available at: www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm367643.pdf (last accessed September 26, 2016).
9. US Food and Drug Administration: Draft Guidance on Budesonide; Formoterol fumarate dihydrate. Available at: www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm452690.pdf (last accessed September 26, 2016).
10. European Medicines Agency: Requirements for clinical documentation for orally inhaled products (OIP) including the requirements for demonstration of therapeutic equivalence between two inhaled products for use in the treatment of Asthma and Chronic Obstructive Pulmonary Disease (COPD) in adults and for use in the treatment of asthma in children and adolescents. Available at: www.ema.europa. eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500003504.pdf (last accessed September 26, 2016).
11. Riley T, Christopher D, Arp J, Casazza A, Colombani A, Cooper A, et al. Challenges with developing in vitro dissolution tests for orally inhaled products (OIPs). AAPS PharmSciTech. 2012;13:978-989.
12. Hastedt J. The lung as a dissolution vessel? Inhalation. 2014;8:18-22.
13. LennernäsH, AaronsL, Augustijns P, Beato S, Bolger M, Box K, Brewster M, Butler J, Dressman J, Holm R, Julia Frank K, Kendall R, Langguth P, Sydor J, Lindahl A, McAllister M, Muenster U, Müllertz A, Ojala K, Pepin X, Reppas C, Rostami-Hodjegan A, Verwei M, Weitschies W, Wilson C, Karlsson C, and Abrahamsson B: Oral biopharmaceutics tools-Time for a new initiative-An introduction to the IMI project OrBiTo, Eur J Pharm Sci. 2014;57:292-299.
14. Chaudhuri S, Lukacova V, and Woltosz V: Simulating the disposition of budesonide from Dry Powder Inhalers (DPIs) and nebulizers [Poster]. Presented at AAPS Annual Meeting, 2013, San Antonio, TX, USA.
15. Bäckman P, and Olsson B: Pitfalls in understanding local exposure. In: R Dalby, P Byron, J Peart, J Suman, and P Young (eds). Respiratory Drug Delivery 2016, Volume1. DHI Publishing LCC, River Grove, IL; pp. 125-132, 2016.
16. IRCP International Commission on Radiological Protection (ICRP): Human respiratory tract model for radiological protection. Ann ICRP. 2014;66:1-120.
17. NCRP report 125: Deposition, Retention and Dosimetry of Inhaled Radioactive Substances. National Council on Radiation Protection and Radiation, Bethesda, MD, 1997.
18. Bondesson E, Bengtsson T, Borgström L, Nilsson L-E, Norrgren K, Olsson B, Svensson M, and Wollmer P: Dose delivery late in the breath can increase dry powder aerosol penetration into the lungs. J Aerosol Med. 2005;18:23-33.
19. Thiel CG: Cascade impactor data and the lognormal distribution: Nonlinear regression for a better fit. J Aerosol Med. 2002;15:369-378.
20. DeHaan WH, and Finlay WH: Predicting extrathoracic deposition from dry powder inhalers. Aerosol Sci. 2004;35: 309-331.
21. Melin J, Prothon S, Kloft C, Cleton A, Johansson CC, Jorup C, Olsson B, Bäckman P, and Wählby Hamrén U: Pharmacokinetics of the inhaled selective glucocorticoid receptor modulator AZD5423 following inhalation using different devices. AAPS, submitted 2016.
22. Bergström CAS, Norinder U, Luthman K, and Artursson P: Experimental and computational screening models for prediction of aqueous drug solubility. Pharm Res. 2009;19: 182-188.
23. Hubatch I, Ragnarsson EG, and Arthursson P: Determination of drug permeability and prediction of drug absorption in Caco-2 monolayers. Nat Protoc. 2007;2:2111-2119.
24. Berg E, and Svensson JO: Establishing standardized methods for comparing aqueous droplet inhalers. Pharmeur Sci Notes. 2006;2:9-16.
25. Weibel ER: Morphometry of the Human Lung. Springer, Berlin, 1963.
26. Yu CP, and Diu CK: A comparative study of aerosol deposition in different lung models. Am Ind Hyg Assoc J. 1982;43:54-65.
27. Yeh HC, and Schum GM: Models of human lung airways and their application to inhaled particle deposition. Bull Math Biol. 1980;42:461-480.
28. Olsson B, Bondesson E, Borgström L, Edsbäcker S, Ekelund K, Gustavsson L, and Hegelund-Myrbäck T: Pulmonary drug metabolism. In: H Smyth and A Hickey (eds). Controlled Pulmonary Drug Delivery, vol. XIV. Springer Verlag, Berlin; pp. 21-50, 2011.